The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial
Open accessAbstract
Importance: Hospitalized patients with COVID-19 are at risk for venous and arterial thromboembolism and death. Optimal thromboprophylaxis dosing in high-risk patients is unknown. Objective: To evaluate the effects of therapeutic-dose low-molecular-weight heparin (LMWH) vs institutional standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19. Design, Setting, and Participants: The HEP-COVID multicenter randomized clinical trial recruited hospitalized adult patients with COVID-19 with D-dimer levels more than 4 times the upper limit of normal or sepsis-induced coagulopathy score of 4 or greater from May 8, 2020, through May 14, 2021, at 12 academic centers in the US. Interventions: Patients were randomized to institutional standard prophylactic or intermediate-dose LMWH or unfractionated heparin vs therapeutic-dose enoxaparin, 1 mg/kg subcutaneous, twice daily if creatinine clearance was 30 mL/min/1.73 m2 or greater (0.5 mg/kg twice daily if creatinine clearance was 15-29 mL/min/1.73 m2) throughout hospitalization. Patients were stratified at the time of randomization based on intensive care unit (ICU) or non-ICU status. Main Outcomes and Measures: The primary efficacy outcome was venous thromboembolism (VTE), arterial thromboembolism (ATE), or death from any cause, and the principal safety outcome was major bleeding at 30 ± 2 days. Data were collected and adjudicated locally by blinded investigators via imaging, laboratory, and health record data. Results: Of 257 patients randomized, 253 were included in the analysis (mean [SD] age, 66.7 [14.0] years; men, 136 [53.8%]; women, 117 [46.2%]); 249 patients (98.4%) met inclusion criteria based on D-dimer elevation and 83 patients (32.8%) were stratified as ICU-level care. There were 124 patients (49%) in the standard-dose vs 129 patients (51%) in the therapeutic-dose group. The primary efficacy outcome was met in 52 of 124 patients (41.9%) (28.2% VTE, 3.2% ATE, 25.0% death) with standard-dose heparins vs 37 of 129 patients (28.7%) (11.7% VTE, 3.2% ATE, 19.4% death) with therapeutic-dose LMWH (relative risk [RR], 0.68; 95% CI, 0.49-0.96; P = .03), including a reduction in thromboembolism (29.0% vs 10.9%; RR, 0.37; 95% CI, 0.21-0.66; P < .001). The incidence of major bleeding was 1.6% with standard-dose vs 4.7% with therapeutic-dose heparins (RR, 2.88; 95% CI, 0.59-14.02; P = .17). The primary efficacy outcome was reduced in non-ICU patients (36.1% vs 16.7%; RR, 0.46; 95% CI, 0.27-0.81; P = .004) but not ICU patients (55.3% vs 51.1%; RR, 0.92; 95% CI, 0.62-1.39; P = .71). Conclusions and Relevance: In this randomized clinical trial, therapeutic-dose LMWH reduced major thromboembolism and death compared with institutional standard heparin thromboprophylaxis among inpatients with COVID-19 with very elevated D-dimer levels. The treatment effect was not seen in ICU patients. Trial Registration: ClinicalTrials.gov Identifier: NCT04401293.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tang, N., Li, D., Wang, X., & Sun, Z. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14768 · Cited by 5,662
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Bikdeli, B., Madhavan, M. V., Jimenez, D., Chuich, T., Dreyfus, I., Driggin, E., Nigoghossian, C. D., Ageno, W., Madjid, M., Guo, Y., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.04.031 · Cited by 2,885
Self-citationCRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis), Helms, J., Tacquard, C., Severac, F., Leonard-Lorant, I., Ohana, M., Delabranche, X., Merdji, H., Clere-Jehl, R., Schenck, M., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06062-x · Cited by 2,792
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study
Wichmann, D., Sperhake, J.-P., Lütgehetmann, M., Steurer, S., Edler, C., Heinemann, A., Heinrich, F., Mushumba, H., Kniep, I., Schröder, A. S., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-2003 · Cited by 2,274
Klok, F. A., Kruip, M. J. H. A., van der Meer, N. J. M., Arbous, M. S., Gommers, D., Kant, K. M., Kaptein, F. H. J., van Paassen, J., Stals, M. A. M., Huisman, M. V., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.04.041 · Cited by 1,601
Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence
Poissy, J., Goutay, J., Caplan, M., Parmentier, E., Duburcq, T., Lassalle, F., Jeanpierre, E., Rauch, A., Labreuche, J., Susen, S., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.047430 · Cited by 1,071
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
The ATTACC, A.-4. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105911 · Cited by 1,046
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
The REMAP-CAP, A.-4. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103417 · Cited by 941
Cited by
Katsoularis, I., Fonseca-Rodríguez, O., Farrington, P., Jerndal, H., Lundevaller, E. H., Sund, M., Lindmark, K., & Fors Connolly, A.-M. (2022) · BMJ · doi:10.1136/bmj-2021-069590 · Cited by 388
Gorog, D. A., Storey, R. F., Gurbel, P. A., Tantry, U. S., Berger, J. S., Chan, M. Y., Duerschmied, D., Smyth, S. S., Parker, W. A. E., Ajjan, R. A., et al. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00665-7 · Cited by 286
SPIRIT 2025 explanation and elaboration: updated guideline for protocols of randomised trials
Hróbjartsson, A., Boutron, I., Hopewell, S., Moher, D., Schulz, K. F., Collins, G. S., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · BMJ · doi:10.1136/bmj-2024-081660 · Cited by 171
Poly (ADP-ribose) polymerase 1 and neurodegenerative diseases: past, present, and future
Hu, M.-L., Pan, Y.-R., Yong, Y.-Y., Liu, Y., Yu, L., Qin, D.-L., Qiao, G., Law, B. Y.-K., Wu, J.-M., Zhou, X.-G., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102078 · Cited by 44
Matsumoto, T., Walston, S. L., Walston, M., Kabata, D., Miki, Y., Shiba, M., & Ueda, D. (2022) · Journal of Digital Imaging · doi:10.1007/s10278-022-00691-y · Cited by 15
Metadata
- Authors
- Spyropoulos, A. C., Goldin, M., Giannis, D., Diab, W., Wang, J., Khanijo, S., Mignatti, A., Gianos, E., Cohen, M., Sharifova, G., Lund, J. M., Tafur, A., Lewis, P. A., Cohoon, K. P., Rahman, H., Sison, C. P., Lesser, M. L., Ochani, K., Agrawal, N., Hsia, J., Anderson, V. E., Bonaca, M., Halperin, J. L., Weitz, J. I., HEP-COVID Investigators, Ohanesian, L., Glater, M., Ho, C., Iakovou, A., Ying, D., Dastagir, M., Convissar, A., Aujla, S., Mathew, E., Thiyagarajan, V., Lewis, T., Gruberg, L., Maccaro, P., Kuziw, D., Pandhi, B., Surguladze, G., Eapen, A. M., Pantea, A., Suen, P., Flynt, J., Krzyzak, M., Sharma, K., Steadham, A., McLean, S. L., Herring, K., Maroney, K., Zorriasateyn, K., Vargas, B., Durante, M., Bhokary, U., Pierchala, L., Fisher, E. A., Oxenberg, D. L., Sabados, A., Chaudhary, O. A., Schultz, S., Cotey, S., Hess, C., Cruse, H., Uy, D., Sharma, S., Molina, K., Jagat, D., & Dehali, B.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2021-12-01
- Volume
- 181
- Issue
- 12
- Pages
- 1612
- ISSN
- 2168-6106 (ISSN-L)
- OpenAlex
- W3202637221
- Cited by
- 461
- References
- 30
- FWCI
- 72.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jamainternmed.2021.6203
- The paper
- Spyropoulos, A. C., Goldin, M., Giannis, D., Diab, W., Wang, J., Khanijo, S., Mignatti, A., Gianos, E., Cohen, M., Sharifova, G., Lund, J. M., Tafur, A., Lewis, P. A., Cohoon, K. P., Rahman, H., Sison, C. P., Lesser, M. L., Ochani, K., Agrawal, N., . . . Dehali, B. (2021). Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2021.6203
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.